Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk | Witfire Elite View Witfire Elite Investment Case Studies Strategy Investment News Investment Witfire Elite View Lilly’s Germany Investment Cut Why Pharma Capital Is Starting to Vote Against Policy Risk Eli Lilly is reportedly halving its planned €2.3 billion Germany investment, […]
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection | Witfire Elite View Witfire Elite Philippines Pharma Watch Case Studies Strategy Breaking Analysis Philippines Pharma Watch Witfire Elite View Philippines AI Liver Cancer Breakthrough How the CANDLE Study Could Change Early Detection A Witfire Breaking Analysis on how the Philippines’ CANDLE
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections A data-rich pharma case study on how IQVIA’s early
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections Read More »
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA’s Digital Liver Break How AI Toxicology Could Change Drug Development Before Phase I FDA accepted the first in silico
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The China Biotech Pipeline Grab How Big Pharma Started Buying Innovation From China A data-heavy pharma case study on how Pfizer, BMS,
The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China Read More »
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A
How GLP-1 Became Pharma’s Most Powerful Growth Story
How GLP-1 Became Pharma’s Most Powerful Growth Story Read More »
GLP-1 Market: The obesity and diabetes drug race is becoming one of the biggest business stories in global pharma. Reuters reported that analysts now estimate global obesity drug sales around USD 105 billion by 2030, lower than earlier USD 130 billion forecasts because of expected price pressure and changing usage patterns. IQVIA’s obesity outlook is
GLP-1 Market Becomes Pharma’s Biggest Business Battle Read More »
The Middle East conflict is now moving directly into pharma boardroom risk. Oil-market stress has intensified, with Vitol’s Bahrain chief warning that the market may still be underpricing the impact of disrupted Middle East supply, including a reported removal of nearly 14 million barrels per day from normal supply flows. Crude prices reportedly spiked as
War Heat Reaches Pharma as Oil, Air Cargo and Cold-Chain Drugs Face Pressure Read More »
The stock market is now looking at the US-Israel-Iran conflict through a sharper pharma lens. This is no longer only a war story, an oil story, or a Wall Street volatility story. For pharmaceutical companies, this conflict has become a supply-chain test, a margin test, and a leadership test. Global markets turned cautious as fresh
